杆菌根除的机会超出了传统抗生素的范围
Camilia Metadea Aji Savitri1,2, Kartika Afrida Fauzia2,3, Ricky Indra Alfaray1,2
1Department of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, Yufu 879-5593, Oita, Japan.
Microorganisms
|October 26, 2024
概括
杆菌 (H. pylori) 感染显著增加胃癌的风险. 新兴的耐药性和生物膜挑战了当前的治疗方法,需要新的治疗策略和药物优化.
科学领域:
- 微生物学 微生物学
- 传染性疾病 传染性疾病
- 在瘤学瘤学.
背景情况:
- 杆菌 (H. pylori) 是胃癌,胃潰瘍和胃炎的主要原因.
- 尽管H. pylori与90%的胃癌病例有关,但根除仍面临来自抗菌素耐药性和生物膜形成的挑战.
- 实证疗法的效率下降,需要探索替代性和补充性治疗方法.
研究的目的:
- 审查用于对抗H. pylori感染的新型化合物和策略.
- 探索克服H. pylori抗菌耐药性和生物膜形成的方法.
- 为消除H. pylori提供替代和补充的治疗选择.
主要方法:
- 对新型抗H.pylori药物研究的文献综述.
- 对针对H. pylori生物膜的策略的分析.
- 对重新定位的毒性因子,菌体治疗,益生菌和纳米颗粒的研究.
- 评估与现有抗生素结合使用的新型化合物.
主要成果:
- 抗菌耐药性和生物膜形成是H. pylori根除的重大障碍.
- 新的治疗途径包括向生物膜,重新利用外膜囊泡,菌体治疗,益生菌和纳米粒子.
- 现有抗生素与新型药物的组合在抵消耐药性方面表现有前途.
结论:
- 新的策略对于克服H. pylori耐药性和生物膜挑战至关重要.
- 重新利用的毒性因子,菌体疗法,益生菌和纳米颗粒为当前治疗提供了潜在的替代品或补充.
- 对这些新型药物和组合的进一步研究对于有效的H. pylori根除至关重要.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
328
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
328
01:26Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
01:23Gastritis III: Clinical Manifestations and Management
166
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
166
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
360
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
360
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
91
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
91
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
407
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
407